4.7 Article

Combined Effects of Alzheimer Risk Variants in the CLU and ApoE Genes on Ventricular Expansion Patterns in the Elderly

期刊

JOURNAL OF NEUROSCIENCE
卷 34, 期 19, 页码 6537-6545

出版社

SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.5236-13.2014

关键词

ApoE; brain aging; clusterin; genetics; neuroimaging; ventricular expansion

资金

  1. A.P.Giannini Foundation
  2. National Institutes of Health (NIH) [R01 MH097268, R01 AG040060]
  3. Alzheimer's Disease Neuroimaging Initiative (ADNI)
  4. National Institutes of Health [U01 AG024904]
  5. National Institute on Aging
  6. National Institute of Biomedical Imaging and Bioengineering

向作者/读者索取更多资源

The C allele at the rs11136000 locus in the clusterin (CLU) gene is the third strongest known genetic risk factor for late-onset Alzheimer's disease (LOAD). A recent genome-wide association study of LOAD found the strongest evidence of association with CLU at rs1532278, in high linkage disequilibrium with rs11136000. Brain structure and function are related to the CLU risk alleles, not just in LOAD patients but also in healthy young adults. We tracked the volume of the lateral ventricles across baseline, 1-year, and 2-year follow-up scans in a large sample of elderly human participants (N = 736 at baseline), from the Alzheimer's Disease Neuroimaging Initiative, to determine whether these CLU risk variants predicted longitudinal ventricular expansion. The rs11136000 major C allele-previously linked with reduced CLU expression and with increased risk for dementia-predicted faster expansion, independently of dementia status or ApoE genotype. Further analyses revealed that the CLU and ApoE risk variants had combined effects on both volumetric expansion and lateral ventricle surface morphology. The rs1532278 locus strongly resembles a regulatory element. Its association with ventricular expansion was slightly stronger than that of rs11136000 in our analyses, suggesting that it may be closer to a functional variant. Clusterin affects inflammation, immuneresponses, and amyloid clearance, which in turn may result in neurodegeneration. Pharmaceutical agents such as valproate, which counteract the effects of genetically determined reduced clusterin expression, may help to achieve neuroprotection and contribute to the prevention of dementia, especially in carriers of these CLU risk variants.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据